**Open Access** 



# Erratum to: A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

Hiroshi Kato<sup>1,2\*</sup>, Masayuki Miyazaki<sup>1,2</sup>, Mio Takeuchi<sup>2</sup>, Hiroaki Tsukuura<sup>3</sup>, Mihoko Sugishita<sup>3</sup>, Yukihiro Noda<sup>1,2</sup> and Kiyofumi Yamada<sup>1</sup>

### Erratum

Unfortunately, after publication of the original version of this article [1], it was noticed that some author corrections were not included in the final article.

• Within the "Methods" section, the Cockcroft-Gault equation should read as follows:

• In addition Table 1 contained some formatting errors. The correct version of Table 1 is included below.

\* Correspondence: hk-hiroshi@med.nagoya-u.ac.jp

<sup>1</sup>Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan

Full list of author information is available at the end of the article



© 2016 Kato et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

<sup>&</sup>lt;sup>2</sup>Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan

#### Table 1 Patient characteristics (n = 204)

| Age                                      |             |
|--|-------------|
| Median, year                             | 61          |
| Range, year                              | 18-92       |
| Gender                                   |             |
| Male, <i>n</i> (%)                       | 123 (60.3)  |
| Female , <i>n</i> (%)                    | 81 (39.7)   |
| Median CLcr <sup>a</sup> , mL/min        | 88.7        |
| NP <sup>b</sup> origin                   |             |
| Cancer related NP, <i>n</i> (%)          | 55 (27.0)   |
| Chemotherapy related NP, n(%)            | 24 (11.7)   |
| Non-cancer related NP, <i>n</i> (%)      | 125 (61.3)  |
| Regular strong opioid                    |             |
| yes, n(%)                                | 36 (17.6)   |
| -fentanyl, <i>n</i>                      | 17          |
| -oxycodone, <i>n</i>                     | 16          |
| -morphine, n                             | 3           |
| Median dose <sup>c</sup> (range), mg/day | 60 (15–300) |
| no, <i>n</i> (%)                         | 168 (82.4)  |
| Initial dose of pregabalin               |             |
| 150 mg/day, <i>n</i> (%)                 | 124 (60.8)  |
| 75 mg/day, <i>n</i> (%)                  | 73 (35.8)   |
| 50 mg/day, <i>n</i> (%)                  | 3 (1.5)     |
| 25 mg/day, <i>n</i> (%)                  | 4 (1.9)     |

<sup>a</sup>CLcr: creatinine clearance using the Cockcroft-Gault equation <sup>b</sup>NP: neuropathic pain <sup>c</sup>converted to oral morphine

#### Author details

<sup>1</sup>Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan. <sup>2</sup>Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Japan. <sup>3</sup>Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

#### Received: 11 February 2016 Accepted: 11 February 2016 Published online: 17 February 2016

#### References

 Kato H, Miyazaki M, Takeuchi M, Tsukuura H, Sugishita M, Noda Y, et al. A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin. J Pharm Health Care Sci. 2015;1:22. doi:10.1186/s40780-015-0022-7.

## Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

